Its lead asset, zolucatetide (FOG-001), is a first-in-class, clinically validated direct inhibitor of the interaction between -catenin and the T-cell factor (TCF) family of transcription factors, implicated in millions of cancer cases annually, including in colorectal cancer, desmoid tumors, hepatocellular carcinoma and a range of other Wnt/-catenin-driven tumors. Data Assets, Partnerships & Infrastructure Identify, evaluate, and prioritize RWD sources (EHR, claims, registries, genomic/omic datasets, imaging, PROs) to support current and future clinical needs.